Efficacy and Safety of Broncho Muco Cleaner Balloon Dilation Therapy

Clinodevice35 enrolled

Overview

In COPD patients with chronic bronchitis, it is aimed to determine whether the broncho muco cleaner balloon dilation method can provide clinical and functional benefit by causing destruction in hyperplasic goblet cells in the bronchial system. Although 2 studies have been published on this subject before, one of them is a retrospective design and the other is a pilot study consisting of only 10 patients . Therefore, it is clear that it should be supported by a controlled prospective study with more patients. Within the scope of the research, broncho muco cleaner balloon dilatation treatment will be performed with fiberoptic bronchoscope under general anesthesia in chronic bronchitis-predominant COPD cases, and the effectiveness and reliability of the procedure will be evaluated.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

COPD

Interventions

The endotracheal tube will be passed with a bronchoscope. During the procedure, the product is connected to the oxygen jack in the hospital, inflated and deflated, turning the thickened goblet cell layer that causes sputum production to foamy liquid. For the procedure, it will be entered through the intubation tube with a fiberoptic bronchoscope, and the airways with a diameter of 3 to 8 mm, primarily the airways, and all the respiratory tract mucosa that can be reached will be treated with a balloon in a total of 3 sessions. For these procedures, balloons selected in accordance with the diameter of the bronchi will be used in the respiratory tract. In patients who meet the patient selection criteria, intervention will be made with a balloon that inflates and deflates at the determined frequency and pressure from the subsegment level that can be reached with the bronchoscope to the inner surface of the airways proximally.

Eligibility

Sex: ALLMin age: 40 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults of both sexes aged 40-75 years * Being diagnosed with stage II-IV chronic bronchitis-predominant COPD according to the GOLD guideline * To have quit smoking for at least 6 months * mMRC 2 and above * Receiving optimal medical treatment for COPD * Being stable for at least 3 weeks * To have completed 6 weeks of pulmonary rehabilitation before the first procedure * Having sufficient mental and physical capacity to sign the voluntary consent form for the procedure. Exclusion Criteria: * be under the age of 40 and over the age of 75 * pregnant patients * breastfeeding a child * Being an active smoker * Concurrent asthma * Chronic kidney disease with GFR \<30 ml/min * Clinically significant arrhythmia, Left heart failure (EF\<45) or pulmonary hypertension (PABs\>45 mmHg) * Liver cirrhosis * Those who use anticoagulants or clopidogrel or equivalent drugs and cannot be stopped before and during the procedure, or the presence of bleeding diathesis * 6 minutes walking test \<100 meters * FEV1\<15% * Those with positive early reversibility in pulmonary function tests * Patients who do not regularly take 15lgu15in therapy for COPD * Emphysema-predominant COPD patients * Presence of active malignancy * Partial CO2 pressure \> 55mmHg or pO2\<55 mmHg in room air * Active pulmonary infection * Pneumothorax or pulmonary surgery in the last 6 months * Patients with other clinically significant lung disease other than COPD * Those who have undergone a previous lung device procedure, including implanted emphysema stents, lung coil delivery, valves, lung denervation, or other devices for emphysema. * Those taking \> 10 mg of prednisolone per day * Those with a known sensitivity to the drug (such as lidocaine, 15lgu15ine and benzodiazepines) needed to perform bronchoscopy.

Outcomes

Primary Outcomes

Reliability of the procedure - Safety

Reliability of the procedure (adverse events occurring) for 52 weeks post-procedure.

Time frame: 52 weeks

Patients' Tolerence - mMRC dyspnea scale

Within the scope of the KBB001 Exertion Study, the broncho muco cleaner procedure to be applied to the patients will be performed with fiberoptic bronchoscopy under general anesthesia. Any undesirable event that may be associated with and after the transaction will be recorded. Primary evaluation criteria in determining the Processing efficiency of your device.

Time frame: 52 Weeks

Patients' Tolerence - COPD Exacerbation Number (severity of exacerbation will be indicated as mild, moderate, severe.)

Within the scope of the KBB001 Exertion Study, the broncho muco cleaner procedure to be applied to the patients will be performed with fiberoptic bronchoscopy under general anesthesia. Any undesirable event that may be associated with and after the transaction will be recorded. primary evaluation criteria in determining the Processing efficiency of your device

Time frame: 52 Weeks

Patients' Tolerence - St George Respiratory Questionnaire

Within the scope of the KBB001 Exertion Study, the broncho muco cleaner procedure to be applied to the patients will be performed with fiberoptic bronchoscopy under general anesthesia. Any undesirable event that may be associated with and after the transaction will be recorded. primary evaluation criteria in determining the Processing efficiency of your device.

Time frame: 52 Weeks

Patients' Tolerence - 6 min walking test

Within the scope of the KBB001 Exertion Study, the broncho muco cleaner procedure to be applied to the patients will be performed with fiberoptic bronchoscopy under general anesthesia. Any undesirable event that may be associated with and after the transaction will be recorded. primary evaluation criteria in determining the Processing efficiency of your device.

Time frame: 52 Weeks

Patients' Tolerence - Pulmonary Function Test (FEV1, FVC values in (lt) and (%) values as well as FEV1/ FVC rate (in %)

Within the scope of the KBB001 Exertion Study, the broncho muco cleaner procedure to be applied to the patients will be performed with fiberoptic bronchoscopy under general anesthesia. Any undesirable event that may be associated with and after the transaction will be recorded. primary evaluation criteria in determining the Processing efficiency of your device.

Time frame: 52 Weeks

Detection of Execerbations

COPD Exacerbation (COPD Exacerbation) is one of the most important problems of COPD patients and includes the risk of mortality and mirdit. It is expected that the number of exacerbations of the patients will decrease with the broncho muco cleaner balloon treatment. The number and severity of exacerbations (mild, moderate, severe) at each visit of the patient will be noted to assess the effect of treatment on exacerbations.

Time frame: 52 weeks

Quality of Life for the device

A St George quality of life survey will be conducted and recorded. Every 4-point change in the SGRQ questionnaire will be considered minimal clinical significance.

Time frame: 52 Weeks

Secondary Outcomes

Improvement in functional parameters - 6 Minute Walk Test (V1-V6)

\- 6 Minute Walk Test (V1-V6)

Time frame: 52 weeks

Improvement in functional parameters - Pulmonary Function Test (V1-V2-V3-V4-V5-V6)

\- Pulmonary Function Test (V1-V2-V3-V4-V5-V6)

Time frame: 52 weeks

Adverse events

Adverse events seen (AE)

Time frame: 52 weeks

Changes in laboratory test results

Change in blood chemistry tests and hemogramcompared to baseline and EoT

Time frame: 52 weeks

Efficacy and Safety of Broncho Muco Cleaner Balloon Dilation Therapy

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes